RxDoctor Payments Data

Alice Echeta

Family · Riverside, CANPI 1003067141

Payments from drug & device makers

$1,899in general payments, 2019–2025

Across 101 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$757
  • Teva Pharmaceuticals USA, Inc.$447
  • Otsuka America Pharmaceutical, Inc.$203
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$184
  • Axsome Therapeutics, Inc.$57
  • Takeda Pharmaceuticals U.S.A., Inc.$56
  • plus $195 from 6 others

What the payments were for

  • Food & beverage$1,85097%
  • Education$493%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,899 in reported general payments places this provider in the 80th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$30,699
Medicare patients
69
Services billed
356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl95$143,891
Abilify MaintenaAripiprazole51$111,500
RexultiBrexpiprazole47$67,771
Invega SustennaPaliperidone Palmitate17$53,020
TrintellixVortioxetine Hydrobromide35$24,095
LybalviOlanzapine/Samidorphan Malate11$17,656
Aripiprazole182$8,888
Lurasidone Hcl58$7,269
Paliperidone ErPaliperidone19$6,954
Trazodone Hcl454$6,210
Quetiapine Fumarate315$5,815
Hydroxyzine Hcl289$5,374
Bupropion XlBupropion Hcl222$4,059
Buspirone Hcl208$2,639
Duloxetine Hcl112$2,638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$203$179,27198 claims
AbbVieVraylar$757$143,89195 claims
Johnson & JohnsonInvega Sustenna$19$53,02017 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$56$24,09535 claims
Alkermes, Inc.Lybalvi$16$17,65611 claims
Almatica Pharma LLCSertraline Hcl$32$1,418249 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,634 family providers in California.

Other family in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →